Zu‐Guo Zheng
0000-0003-3991-1728
Publication & Citation Trends
Publications
0 total
GCN5 drives MASLD progression through LXRα/SREBP1c signaling pathway–mediated de novo lipogenesis
Cited by 0
Semantic Scholar
Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid β-oxidation by activating mitochondrial ACSL1.
Cited by 16
Semantic Scholar
Simiao Wan alleviates obesity-associated insulin resistance via PKCε/IRS-1/PI3K/Akt signaling pathway based on network pharmacology analysis and experimental validation OA
Cited by 2
Semantic Scholar
Emerging role of GCN5 in human diseases and its therapeutic potential. OA
Cited by 17
Semantic Scholar
Recent advances in research on natural product inhibitors of SREBPs OA
Cited by 3
Semantic Scholar
Geranylgeranyl pyrophosphate depletion by statins compromises skeletal muscle insulin sensitivity OA
Cited by 6
Semantic Scholar
Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER α degradation
Cited by 14
Semantic Scholar
7-aminocephalosporanic acid, a novel HSP90β inhibitor, attenuates HFD-induced hepatic steatosis.
Cited by 5
Semantic Scholar
Advancing targeted protein degradation for metabolic diseases therapy. OA
Cited by 52
Semantic Scholar
Research Topics
Autophagy in Disease and Therapy
(7)
Liver Disease Diagnosis and Treatment
(6)
Cholesterol and Lipid Metabolism
(6)
Endoplasmic Reticulum Stress and Disease
(5)
Protein Kinase Regulation and GTPase Signaling
(4)
Affiliations
China Pharmaceutical University
Lomonosov Moscow State University
Karolinska Institutet
National Center for Drug Screening
Tibetan Traditional Medical College